Literature DB >> 17486348

[Steroids for optic nerve diseases?].

W A Lagrèze1.   

Abstract

Diseases of the optic nerve are the third most common cause of blindness in Germany. Common optic nerve diseases include optic nerve neuritis and traumatic optic neuropathy. These diseases are often treated with steroids. In the case of traumatic optic neuropathy, recent results indicate that such treatment is not of value, and can even be dangerous due to the side effects if the doses are high. Based on current results, the value of high dose steroid treatment for optic nerve neuritis is also questionable.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17486348     DOI: 10.1007/s00347-007-1525-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  46 in total

Review 1.  Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders.

Authors:  R Gold; F Buttgereit; K V Toyka
Journal:  J Neuroimmunol       Date:  2001-07-02       Impact factor: 3.478

Review 2.  Corticosteroids for treating optic neuritis.

Authors:  S S Vedula; S Brodney-Folse; R L Gal; R Beck
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.

Authors:  M B Bracken; M J Shepard; T R Holford; L Leo-Summers; E F Aldrich; M Fazl; M Fehlings; D L Herr; P W Hitchon; L F Marshall; R P Nockels; V Pascale; P L Perot; J Piepmeier; V K Sonntag; F Wagner; J E Wilberger; H R Winn; W Young
Journal:  JAMA       Date:  1997-05-28       Impact factor: 56.272

Review 4.  Optical coherence tomography in multiple sclerosis.

Authors:  Elliot Frohman; Fiona Costello; Robert Zivadinov; Olaf Stuve; Amy Conger; Heather Winslow; Anand Trip; Teresa Frohman; Laura Balcer
Journal:  Lancet Neurol       Date:  2006-10       Impact factor: 44.182

5.  Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG).

Authors:  M Wakakura; K Mashimo; S Oono; Y Matsui; A Tabuchi; K Kani; K Shikishima; K Kawai; Y Nakao; Y Tazawa; M Kiyosawa; H Abe; N Ohba; K Yago; S Maeda; M Sugita; S Ishikawa
Journal:  Jpn J Ophthalmol       Date:  1999 Mar-Apr       Impact factor: 2.447

Review 6.  Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders.

Authors:  R M Sapolsky
Journal:  Arch Gen Psychiatry       Date:  2000-10

7.  A temporal study of axonal degeneration and glial scar formation following a standardized crush injury of the optic nerve in the adult rat.

Authors:  Marcus Ohlsson; Per Mattsson; Mikael Svensson
Journal:  Restor Neurol Neurosci       Date:  2004       Impact factor: 2.406

8.  Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway.

Authors:  Ricarda Diem; Muriel Hobom; Katharina Maier; Robert Weissert; Maria K Storch; Roman Meyer; Mathias Bähr
Journal:  J Neurosci       Date:  2003-08-06       Impact factor: 6.167

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis.

Authors:  S Anand Trip; Patricio G Schlottmann; Stephen J Jones; Daniel R Altmann; David F Garway-Heath; Alan J Thompson; Gordon T Plant; David H Miller
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.